Literature DB >> 16941471

Comprehensive NF1 screening on cultured Schwann cells from neurofibromas.

Ophélia Maertens1, Hilde Brems, Jo Vandesompele, Thomas De Raedt, Ine Heyns, Thorsten Rosenbaum, Sofie De Schepper, Anne De Paepe, Geert Mortier, Sandra Janssens, Frank Speleman, Eric Legius, Ludwine Messiaen.   

Abstract

Neurofibromatosis type 1 (NF1) is mainly characterized by the occurrence of benign peripheral nerve sheath tumors or neurofibromas. Thorough investigation of the somatic mutation spectrum has thus far been hampered by the large size of the NF1 gene and the considerable proportion of NF1 heterozygous cells within the tumors. We developed an improved somatic mutation detection strategy on cultured Schwann cells derived from neurofibromas and investigated 38 tumors from nine NF1 patients. Twenty-nine somatic NF1 lesions were detected which represents the highest NF1 somatic mutation detection rate described so far (76%). Furthermore, our data strongly suggest that the acquired second hit underlies reduced NF1 expression in Schwann cell cultures. Together, these data clearly illustrate that two inactivating NF1 mutations, in a subpopulation of the Schwann cells, are required for neurofibroma formation in NF1 tumorigenesis. The observed somatic mutation spectrum shows that intragenic NF1 mutations (26/29) are most prevalent, particularly frameshift mutations (12/29, 41%). We hypothesize that this mutation signature might reflect slightly reduced DNA repair efficiency as a trigger for NF1 somatic inactivation preceding tumorigenesis. Joint analysis of the current and previously published NF1 mutation data revealed a significant difference in the somatic mutation spectrum in patients with a NF1 microdeletion vs. non-microdeletion patients with respect to the prevalence of loss of heterozygosity events (0/15 vs. 41/81). Differences in somatic inactivation mechanism might therefore exist between NF1 microdeletion patients and the general NF1 population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941471     DOI: 10.1002/humu.20389

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  43 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

2.  Phenotypic variability among café-au-lait macules in neurofibromatosis type 1.

Authors:  Kevin P Boyd; Liyan Gao; Rui Feng; Mark Beasley; Ludwine Messiaen; Bruce R Korf; Amy Theos
Journal:  J Am Acad Dermatol       Date:  2010-06-03       Impact factor: 11.527

3.  The development of cutaneous neurofibromas.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Tom Callens; Elina Jokinen; Anthony M Heape; Ludwine Messiaen; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

5.  The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1 +/- or NF1 -/- genotype derived from human cutaneous neurofibromas.

Authors:  Paula Pennanen; Sirkku Peltonen; Roope A Kallionpää; Juha Peltonen
Journal:  Mol Cell Biochem       Date:  2017-11-28       Impact factor: 3.396

6.  Clitoromegaly: beyond testosterone.

Authors:  Darshana Sudip Thakur; Chaitanya G Yerawar; Meghana Phiske; Nikhil M Bhagwat
Journal:  BMJ Case Rep       Date:  2018-06-14

7.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

8.  Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Authors:  Carlos E Prada; Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; R Scott Dunn; Debra A Mayes; Jose A Cancelas; Eva Dombi; Mi-Ok Kim; Brian L West; Gideon Bollag; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2012-10-26       Impact factor: 17.088

9.  Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

Authors:  Jordi Barretina; Barry S Taylor; Shantanu Banerji; Alexis H Ramos; Mariana Lagos-Quintana; Penelope L Decarolis; Kinjal Shah; Nicholas D Socci; Barbara A Weir; Alan Ho; Derek Y Chiang; Boris Reva; Craig H Mermel; Gad Getz; Yevgenyi Antipin; Rameen Beroukhim; John E Major; Charles Hatton; Richard Nicoletti; Megan Hanna; Ted Sharpe; Tim J Fennell; Kristian Cibulskis; Robert C Onofrio; Tsuyoshi Saito; Neerav Shukla; Christopher Lau; Sven Nelander; Serena J Silver; Carrie Sougnez; Agnes Viale; Wendy Winckler; Robert G Maki; Levi A Garraway; Alex Lash; Heidi Greulich; David E Root; William R Sellers; Gary K Schwartz; Cristina R Antonescu; Eric S Lander; Harold E Varmus; Marc Ladanyi; Chris Sander; Matthew Meyerson; Samuel Singer
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

Review 10.  Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis.

Authors:  Philip D King; Beth A Lubeck; Philip E Lapinski
Journal:  Sci Signal       Date:  2013-02-26       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.